Drugs / dapolsertib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03008187 | Mar 2017 → Apr 2023 | acute myeloid leukemia | Menarini Group | Completed | No outcome recorded |
Press releases naming this drug 20 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dapolsertib | “Dapolsertib (MEN1703) is a novel, first-in-class dual inhibitor of PIM (proviral integration site for Moloney murine leukemia virus) and FLT3 kinases, with activity in both...” PMID 41536779 ↗ Oct 2025 |
| Known as | MEN1703 | “Dapolsertib (MEN1703) is a novel, first-in-class dual inhibitor of PIM (proviral integration site for Moloney murine leukemia virus) and FLT3 kinases, with activity in both...” PMID 41536779 ↗ Oct 2025 |
| Known as | SEL-24 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4467168 ↗ |
| Known as | SEL-24 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4467168 ↗ |
| Known as | SEL24-B289 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4467168 ↗ |
| Known as | SEL24-B489 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4467168 ↗ |
| Action | Inhibit | “Dapolsertib (MEN1703) is a novel, first-in-class dual inhibitor of PIM (proviral integration site for Moloney murine leukemia virus) and FLT3 kinases, with activity in both...” PMID 41536779 ↗ Oct 2025 |
| Modality | Small molecule | — CHEMBL4467168 ↗ |
| Route | Oral | “Seventy-three patients received oral doses of dapolsertib ranging from 25 to 150 mg per day (14 consecutive days over 21-day cycles).” PMID 41536779 ↗ Oct 2025 |
| Target | FLT3 | “Dapolsertib (MEN1703) is a novel, first-in-class dual inhibitor of PIM (proviral integration site for Moloney murine leukemia virus) and FLT3 kinases, with activity in both...” PMID 41536779 ↗ Oct 2025 |